Recent study showed that the PPARα activation could improve hepatic steatosis by promoting of fat oxidation together with the inhibiting of lipogenesis through SREBP1c activation in the soy isoflavone-treated high fat diet NAFLD model rats.(25) It is up-regulated by natural ligands, fatty acids, and synthetic ligands, such as fibrates.(26,27) Therefore, FXR-ligand treatment is suggested to activate the PPARα-regulated lipolysis in fatty liver. This evidence concerns the gene SREBF1 and fatty liver disease.